All In Biotech

Drug Trial Radar · NCT07145229

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

A Randomized, Double-blind, Multicenter, Colchicine and Placebo-controlled Study to Evaluate the Efficacy and Safety of ABP-745 in Subjects With an Acute Gout Flare

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 479 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

479

Actual

Start

Aug 26, 2025

Primary completion

Jul 14, 2026

Study completion Aug 11, 2026

Sponsor

Lead sponsor
Atom Therapeutics Co., LtdIndustry
Sponsor type
Industry
First posted
Aug 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Conditions

  • Acute Gouty Arthritis
  • Gout Flare
  • Gout Flares
  • Acute Gout Flare

Interventions

  • ABP-745 Dose ADrug

    ABP-745 Dose A + Colchicine placebo - tablets (PO)

  • ABP-745 Dose BDrug

    ABP-745 Dose B + Colchicine placebo - tablets (PO)

  • ColchicineDrug

    ABP-745 placebo + Colchicine - tablets (PO)

  • PlaceboDrug

    ABP-745 placebo + Colchicine placebo - tablets (PO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Visual Analog Scale (VAS) pain score of the target jointTime frame: 24 hours post the first dose of study drug

Locations

38 sites in 3 countries. Site status is shown where the registry gives one.

  • Onyx Clinical Research

    Peoria, Arizona

  • Exinia Research

    La Mesa, California

  • Evergreen Clinical Trial

    Norcross, Georgia

  • Bioluminux Clinical Research

    Naperville, Illinois

  • Exinia Research

    Des Moines, Iowa

  • Northshore Research Associates

    Alexandria, Louisiana

  • DelRicht Research

    Baton Rouge, Louisiana

  • DelRicht Research

    New Orleans, Louisiana

  • Interphase Clinical Trials

    Lutherville, Maryland

  • DelRicht Research Gulfport

    Gulfport, Mississippi

  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico

  • West Clinical Research

    Morehead City, North Carolina

  • DelRicht Research

    Tulsa, Oklahoma

  • Premier Family Physicians

    Austin, Texas

  • Emeritus Sydney

    Botany, New South Wales, Australia

  • Canopy Clinical Research Northern Beaches

    Brookvale, New South Wales, Australia

  • Novatrials

    Kotara, New South Wales, Australia

  • Genesis Research Services

    Newcastle, New South Wales, Australia

  • Emeritus Melbourne

    Camberwell, Victoria, Australia

  • Canopy Clinical Research Altona North

    North Altona, Victoria, Australia

  • Peking University Third hospital

    Beijing, Beijing Municipality, China

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • The second affiliated hospital of guangxi medical university

    Nanning, Guangxi, China

  • Hebei Petro China Central Hospital

    Langfang, Hebei, China

  • Wuhan UHospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangtan Central Hospital

    Xiangtan, Hunan, China

  • Xiangya Hospital Zhuzhou Central South University

    Zhuzhou, Hunan, China

  • Huai'an First People's Hospital

    Huai'an, Jiangsu, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, China

  • Zaozhuang Municipal Hospital

    Zaozhuang, Shandong, China

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Linfen Central hospital

    Linfen, Shanxi, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China

  • Shaanxi Provincial People's Hospital

    Xi’an, Shanxi, China

  • Xi'an Daxing Hospital

    Xi’an, Shanxi, China

  • Chengdu Fifth People's Hospital

    Chengdu, Sichuan, China

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

  • Wenzhou People's Hospital

    Wenzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.